Huntington's disease: An update of therapeutic strategies

Gene

Volumn 556, Issue 2, 2015, Pages 91-97

  Kumar, Ashok ^a   Kumar Singh, Sandeep ^a   Kumar, Vijay ^a   Kumar, Dinesh ^b   Agarwal, Sarita ^a   Rana, Manoj Kumar ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b DR RAM MANOHAR LOHIA AVADH UNIVERSITY   (India)

Author keywords

Antisense oligonucleotide (ASO); Histone deacetylase inhibitors (HDACi); Htt gene; Huntington's disease (HD); RNA interference (RNAi); Transglutaminase inhibitors (Tgasei)

Indexed keywords

4 PHENYLBUTYRIC ACID; ACYLTRANSFERASE INHIBITOR; ANTIOXIDANT; ANTISENSE OLIGONUCLEOTIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 6 INHIBITOR; CASPASE INHIBITOR; COMPOUND C2-8; CONGO RED; CREATINE; EPIGALLOCATECHIN GALLATE; GLUTAMIC ACID; HISTONE DEACETYLASE INHIBITOR; HUNTINGTIN; ICOSAPENTAENOIC ACID; IFENPRODIL; LAMOTRIGINE; MEMANTINE; MERCAPTAMINE; MINOCYCLINE; MITHRAMYCIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RAPAMYCIN; REMACEMIDE; RILUZOLE; SIRTUIN; SYNTHETIC PEPTIDE; TETRABENAZINE; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; HTT PROTEIN, HUMAN; NERVE PROTEIN; NEUROPROTECTIVE AGENT;

APOPTOSIS; AUTOSOMAL DOMINANT INHERITANCE; BRAIN MITOCHONDRION; BRAIN NERVE CELL; CAG REPEAT; CALCIUM SIGNALING; CHROMOSOME 4P; COGNITIVE DEFECT; CORPUS STRIATUM; DRUG TARGETING; EATING; EMBRYONIC STEM CELL; EXCITOTOXICITY; FETUS CELL; GENE; GERM CELL; HISTONE ACETYLATION; HTT GENE; HUMAN; HUNTINGTON CHOREA; LIMB MOVEMENT; MITOCHONDRIAL RESPIRATION; MOLECULAR BIOLOGY; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NEOCORTEX; NEOSTRIATUM; NEURAL STEM CELL; NEURAL STEM CELL TRANSPLANTATION; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; REVIEW; RNA INTERFERENCE; TRANSCRIPTION REGULATION; WALKING; WRITING; ANIMAL; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); GENETICS; HUNTINGTON DISEASE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROTEINOSIS;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; CLINICAL TRIALS AS TOPIC; HUMANS; HUNTINGTON DISEASE; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; PROTEIN AGGREGATION, PATHOLOGICAL;

EID: 84919622781     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.11.022     Document Type: Review

References (76)

1. Bachoud-Lévi A.C., Rémy P., Nguyen J.P., et al. Motor and cognitive improvements in patients with Huntington's disease after neural, transplantation. Lancet 2000, 356(9246):1975-1979.
2. Bachoud-Lévi A.C., Gaura V., Brugières P., et al. Effect of fetal neural transplants in patients with Huntington's disease 6years after surgery: a long-term follow-up study. Lancet Neurol. 2006, 5(4):303-309.
3. Becher M.W., Kotzuk J.A., Sharp A.H., et al. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol. Dis. 1998, 4(6):387-397.
4. Bezprozvanny I., Hayden M.R. Deranged neuronal calcium signalling and Huntington disease. Biochem. Biophys. Res. Commun. 2004, 322:1310-1317.
5. Borra M.T., Smith B.C., Denu J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 2005, 280:17187-17195.
6. Cankurtaran E.S., Ozalp E., Soygur H., et al. Clinical experience with risperidone and memantine in the treatment of Huntington's disease. J. Natl. Med. Assoc. 2006, 98:1353-1355.
7. Cantuti-Castelvetri I., Lin M.T., Zheng K., Keller-McGandy C.E., Betensky R.A., Johns D.R. Somatic mitochondrial DNA mutations in single neurons and glia. Neurobiol. Aging 2005, 26:1343-1355.
8. Chakrabarti S., Bhattacharyya D., Dasgupta D. Structural basis of DNA recognition by anticancer antibiotics, chromomycin A(3), mithramycin: roles of minor groove width and ligand flexibility. Biopolymers 2000, 56:85-95.
9. Chen M., Ona V.O., Li M., et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 2000, 6:797-801.
10. Choo Y.S., Johnson G.V., MacDonald M., Detloff P.J., Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 2004, 13:1407-1420.
11. Chopra V., Fox J.H., Lieberman G., et al. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:16685-16689.
12. Clarke C.R.A. Neurological disease. Kumar and Clark Clinical Medicine 2005, 1173-1271. W.B. Saunders, Edinburgh and New York. 6th ed. P. Kumar, M. Clark (Eds.).
13. DiFiglia M., Sapp E., Chase K.O., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neuritis in brain. Science 1997, 277:1990-1993.
14. Ehrnhoefer D.E., Duennwald M., Markovic P., et al. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum. Mol. Genet. 2006, 15:2743-2751.
15. Ferrante R.J., Andreassen O.A., Jenkins B.G., et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 2000, 20:4389-4397.
16. Ferrante R.J., Andreassen O.A., Dedeoglu A., et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 2002, 22:1592-1599.
17. Filloux F., Townsend J.J. Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp. Neurol. 1993, 119:79-88.
18. Gelehrter T.D., Collins F.S., Ginsburg D. Principles of Medical Genetics 1998, Williams & Wilkins, Baltimore. 2nd ed.
19. Glitz D. Protein synthesis: translation and posttranslational modifications. Textbook of Biochemistry: With Clinical Correlations 2011, 209-254. John Wiley & Sons, Inc., Hoboken NJ. 7th ed. T.M. Devlin (Ed.).
20. Graham R.K., Deng Y., Slow E.J., et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006, 125:1179-1191.
21. Griffin M., Casadio R., Bergamini C.M. Transglutaminases: nature's biological glues. Biochem. J. 2002, 368(2):377-396.
22. Guyot M.C., Palfi S., Stutzmann J.M., et al. Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. Neuroscience 1997, 81:141-149.
23. Handley O.J., Naji J.J., Dunnett S.B., et al. Pharmaceutical, cellular and genetic therapies for Huntington's disease. Clin. Sci. 2006, 110:73-88.
24. Handley O.J., Naji J.J., Dunnett S.B., Rosser A.E. Pharmaceutical, cellular and genetic therapies for Huntington's disease. Clin. Sci. 2006, 110:73-88.
25. Harper S.Q., Staber P.D., He X., et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5820-5825.
26. Hersch S., Fink K., Vonsattel J.P., et al. Minocycline is protective in a mouse model of Huntington's disease. Ann. Neurol. 2003, 54:841-843.
27. Hersch S.M., Gevorkian S., Marder K., et al. Creatine in Huntington disease is safe, tolerable, and bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006, 66:250-252.
28. Hockly E., Richon V.M., Woodman B., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2041-2046.
29. Horton T.M., Graham B.H., Corral-Debrinski M., Shoffner J.M., Kaufman A.E., Beal M.F. Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients. Neurology 1995, 45:1879-1883.
30. Hu J., Matsui M., Corey D.R. Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA. Ann. N. Y. Acad. Sci. 2009, 1175:24-31.
31. Iwata A., Riley B.E., Johnston J.A., et al. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J. Biol. Chem. 2005, 280:40282-40292.
32. Jakel R.J., Maragos W.F. Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci. 2000, 23:239-245.
33. Karpuj M.V., Becher M.W., Springer J.E., et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 2002, 8:143-149.
34. Karpuj M.V., Becher M.W., Steinman L. Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications. Neurochem. Int. 2002, 40(1):31-36.
35. Kieburtz K., Feigin A., McDermott M., et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov. Disord. 1996, 11:273-277.
36. Kim J.H., Auerbach J.M., Rodriguez-Gomez J.A., et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 2002, 418:50-56.
37. Kremer B., Goldberg P., Andrew S.E., et al. A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N. Engl. J. Med. 1994, 330:1401-1406.
38. Kremer B., Clark C.M., Almqvist E.W., et al. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology 1999, 53:1000-1011.
39. Lee S.T., Chu K., Park J.E., et al. Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease. Brain Res. 2006, 1118:199-207.
40. Lutz R.E. Trinucleotide repeat disorders. Semin. Pediatr. Neurol. 2007, 14(1):26-33.
41. Mao Z., Choo Y.S., Lesort M. Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells. Eur. J. Neurosci. 2006, 23:1701-1710.
42. Mary V., Wahl F., Stutzmann J.M. Effect of riluzole on quinolinate induced neuronal damage in rats: comparison with blockers of glutamatergic neurotransmission. Neurosci. Lett. 1995, 201:92-96.
43. Mueller R.F., Young I.D. Emery's Elements of Medical Genetics 2001, Churchill Livingstone, Edinburgh. 11th ed.
44. Nasir J., Floresco S.B., O'Kusky J.R., et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioural and morphological changes in heterozygotes. Cell 1995, 81(5):811-823.
45. Nellemann C., Abell K., Norremolle A., et al. Inhibition of Huntington synthesis by antisense oligodeoxynucleotides. Mol. Cell. Neurosci. 2000, 16:313-323.
46. Neylan T.C. Neurodegenerative disorders: George Huntington's description of hereditary chorea. J. Neuropsychiatry Clin. Neurosci. 2003, 15(1):108.
47. Orr A.L., Li S., Wang C.E., Li H., Wang J., Rong J. NH2-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci. 2008, 28:2783-2792.
48. Palfi S., Riche D., Brouillet E., et al. Hantraye P. Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. Exp. Neurol. 1997, 146:135-141.
49. Perry T.L., Hansen S., Kloster M. Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain. N. Engl. J. Med. 1973, 288:337-342.
50. Raamsdonk V.J.M., Pearson J., Rogers D.A., et al. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp. Neurol. 2005, 196:266-272.
51. Ravikumar B., Vacher C., Berger Z., et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 2004, 36:585-595.
52. Reubinoff B.E., Pera M.F., Fong C.Y., et al. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat. Biotechnol. 2000, 18:399-404.
53. Ryu H., Lee J., Hagerty S.W., Soh B.Y., McAlpin S.E., Cormier K.A. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:19176-19181.
54. Sanchez I., Mahlke C., Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003, 421:373-379.
55. Sarkar S., Davies J.E., Huang Z., et al. A novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J. Biol. Chem. 2007, 282:5641-5652.
56. Sarkar S., Krishna G., Imarisio S., et al. A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum. Mol. Genet. 2008, 17:170-178.
57. Schilling G., Coonfield M.L., Ross C.A., et al. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci. Lett. 2001, 315:149-153.
58. Shamblott M.J., Axelman J., Wang S., et al. Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:13726-13731.
59. Southwell A.L., Ko J., Patterson P.H. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J. Neurosci. 2009, 29:13589-13602.
60. Spokes E.G. Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. Brain 1980, 103:179-210.
61. Stack E.C., Del Signore S.J., Luthi-Carter R., Soh B.Y., Goldstein D.R., Matson S. Modulation of nucleosome dynamics in Huntington's disease. Hum. Mol. Genet. 2007, 16:1164-1175.
62. Tanaka M., Machida Y., Niu S., et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 2004, 10:148-154.
63. Tang T.S., Chen X., Liu J., et al. Dopaminergic signalling and striatal neurodegeneration in Huntington's disease. J. Neurosci. 2007, 27:7899-7910.
64. The HDCRG Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006, 66:366-372.
65. Thomas E.A., Coppola G., Desplats P.A., et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15564-15569.
66. Turnpenny P., Ellard S. Emery's Elements of Medical Genetics 2007, Churchill Livingstone Elsevier, Philadelphia. 13th ed.
67. Varma H., Voisine C., Demarco C.T., et al. Selective inhibitors of death in mutant huntingtin cells. Nat. Chem. Biol. 2007, 3:99-100.
68. Verme I., Steur E.N., Jirikowski G.F., et al. Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson's disease indicating apoptosis. Mov. Disord. 2004, 19(10):1252-1254.
69. Vishal M.G., Nicolas Offner, James A., et al. Mootha Meclizine is neuroprotective in models of Huntington's disease. Hum. Mol. Genet. 2011, 20(2):294-300.
70. Wang H., Lim P.J., Yin C., et al. Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin. Hum. Mol. Genet. 2006, 15(6):1025-1041.
71. Wichterle H., Lieberam I., Porter J.A., et al. Directed differentiation of embryonic stem cells into motor neurons. Cell 2002, 110:385-397.
72. Lichuan Yang, Calingasan Noel Y., Wille Elizabeth J., et al. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J. Neurochem. 2009, 109(5):1427-1439.
73. Young I.D. Medical Genetics 2005, Oxford University Press, Oxford.
74. Zeron M.M., Hansson O., Chen N., Wellington C.L., et al. Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002, 33:849-860.
75. Zhang S.C., Wernig M., Duncan I.D., et al. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat. Biotechnol. 2001, 19:1129-1133.
76. Zuccato C., Ciammola A., Rigamonti D., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293(5529):493-498.